Normalized Income after Taxes: A company's after tax profit or loss smoothed out by elimination of all non-recurring items.
Vanda Pharmaceuticals Inc. (VNDA) had Normalized Income after Taxes of $-18.90M for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
$198.77M |
|
$-18.90M |
|
$11.31M |
|
$187.46M |
|
$239.43M |
|
$-40.66M |
|
$17.74M |
|
$-22.92M |
|
$-22.92M |
|
$-18.90M |
|
$-18.90M |
|
$-18.90M |
|
|
Normalized Income after Taxes |
$-18.90M |
$-40.66M |
|
$-39.52M |
|
58.15M |
|
58.15M |
|
$-0.33 |
|
$-0.33 |
|
| Balance Sheet Financials | |
$438.89M |
|
$2.13M |
|
$217.31M |
|
$656.20M |
|
$99.98M |
|
-- |
|
$17.68M |
|
$117.66M |
|
$538.55M |
|
$424.45M |
|
$538.55M |
|
58.31M |
|
| Cash Flow Statement Financials | |
$-15.76M |
|
$-17.43M |
|
$-0.15M |
|
$136.29M |
|
$102.78M |
|
$-33.51M |
|
$12.43M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.39 |
|
-- |
|
-- |
|
-- |
|
-- |
|
94.31% |
|
-20.46% |
|
-20.46% |
|
-19.88% |
|
-11.53% |
|
-9.51% |
|
$-20.48M |
|
-- |
|
-- |
|
-- |
|
0.30 |
|
6.55 |
|
4.22 |
|
86.49 |
|
-3.51% |
|
-4.45% |
|
-2.88% |
|
-3.51% |
|
$9.24 |
|
$-0.35 |
|
$-0.27 |
|